A Vaccine Could Deliver an 82% Gain
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, recently announced additional positive data from a Phase 2 extension study of its NasoVAX intranasal influenza vaccine candidate.
Data from this study demonstrated that 100% of the evaluated subjects remained seroprotected, and the seroconversion rate was unchanged more than one year after vaccination.
Vipin K. Garg, Ph.D., President and CEO of Altimmune, commented, “We are excited about the continued positive NasoVAX results and believe that if approved, NasoVAX has the potential to capture a significant portion of the global flu vaccine market.”
Garg continued, “Based on the continued positive data, we are seeking development and commercialization partnerships for our NasoVAX program. This will allow us to focus on our strategy of building a pipeline of multiple early to mid-stage assets.
We are currently engaged in a rigorous acquisition review process focused on novel immunotherapeutic approaches for cancer, including immunostimulants and oncolytic viruses, and innovative product candidates for liver diseases.
The proceeds from our recent successful financing efforts have put us in a strong position to execute our acquisition plans.”
This could be big news for the $3 biotech stock.
Globe Newswire recently summarized other programs that could also increase the company’s profitability in the future:
“In December 2018, the Company reported final results of a pre-planned analysis of its first-in-human evaluation of HepTcell in patients with chronic hepatitis B infection, which met the primary safety endpoint and demonstrated encouraging results where two adjuvanted HepTcell arms had markedly greater increases in T-cell immunity over baseline than the placebo group. HBV-specific immune activation is widely recognized as being a key requirement of HBV functional cure, and the Company plans to advance the HepTcell program into Phase 2 development. “ALT-702
“ALT-702 is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancers. It is a conjugated TLR-7/8 agonist designed to reverse immune-suppressive effects in the tumor microenvironment and promote antitumoral responses without the systemic side effects associated with other injected TLR-7 and TLR-7/8 agonists. This localized immune stimulation is anticipated to turn “cold” tumors to “hot” and to synergize with immune checkpoint inhibitors. The Company is currently developing a full preclinical dataset in murine tumor models with the intention of advancing this program into the clinic.”
This cheap biotech has several products that could be approved soon. Investors should keep a close eye on this company.
ALT should be considered a buy if momentum increases and the stock breaks out of its current trading range.
Look for an entry at $3.03 with a price target of at least $5.54 based on the pattern in the chart.